Emerging Global Evidence Resonates in New Zealand
A groundbreaking review published in early 2026 has concluded that nicotine-based e-cigarettes, commonly known as vapes, are likely carcinogenic to humans, specifically increasing the risk of lung and oral cancers. Led by Adjunct Professor Bernard Stewart from the University of New South Wales (UNSW), the qualitative risk assessment synthesizes peer-reviewed studies from 2017 to mid-2025, marking the strongest evidence to date linking vaping directly to cancer development independent of traditional smoking.
This international finding has particular relevance for New Zealand, where vaping prevalence remains high, especially among youth, prompting local universities to intensify research into its long-term health impacts. Institutions like the University of Auckland, University of Otago, and Massey University are at the forefront, contributing studies on cessation challenges, gateway effects, and lung modeling that contextualize these global warnings within Aotearoa's unique demographic and policy landscape.
The UNSW Review: Mechanisms of Carcinogenicity
The Stewart-led paper, titled "The carcinogenicity of e-cigarettes: a qualitative risk assessment," evaluates multiple lines of evidence: biomarkers of exposure (e.g., nicotine-derived nitrosamines, volatile organic compounds, metals like nickel and chromium absorbed into blood and urine), biomarkers of potential harm (DNA mutations, oxidative stress, inflammation in oral and respiratory tissues), animal bioassays (mice developing lung adenocarcinomas from vape aerosol inhalation), and clinical case reports (e.g., oral cancer in young non-smokers with heavy vaping history). These align with the World Health Organization's ten key characteristics of carcinogens, indicating vapes mediate harm through genotoxicity, immune modulation, and cellular proliferation disruption.
Unlike prior reviews that compared vaping favorably to smoking, this analysis isolates vaping's standalone risks, concluding it can no longer be deemed substantially safer for cancer outcomes. While epidemiological data lags due to vaping's 20-year history, mechanistic convergence demands immediate action, echoing the decades-long delay in addressing tobacco's harms.
Vaping Landscape in New Zealand: Prevalence and Demographics
New Zealand faces a vaping epidemic, with the 2024/25 New Zealand Health Survey reporting daily vaping at 11.7% among adults aged 15+, up from prior years despite regulatory efforts. Youth rates, though declining over three years (12% past-week use in Years 9-13 per 2024 ARFNZ survey, down from 27% in 2021), remain concerning: 20% weekly among Māori students vs. 11% NZ European. University-aged 18-24-year-olds show ever-vaping around 40%, with 6% current and 1.6% daily use in older cohorts, often alongside studies or social settings on campuses.
- Māori and Pacific youth disproportionately affected, mirroring inequities in smoking (Māori daily smoking 5x higher historically).
- Dual use prevalent: 63.9% of vapers also smoke, amplifying risks.
- Flavored, nicotine pods drive uptake, with black-market products evading regulations.
The Cancer Society of New Zealand's February 2026 report underscores vaping's lesser but real harms, including plausible cancer pathways from low-dose carcinogens like formaldehyde and acrolein.
New Zealand Universities Pioneer Vaping Research
NZ higher education institutions are pivotal in dissecting vaping's threats. The University of Auckland's Bioengineering Institute, under Associate Professor Kelly Burrowes, models long-term lung impacts using computational simulations and digital twins to predict tissue damage from aerosol deposition—critical for cancer risk forecasting absent decades of data. Their 2025 gateway study analyzed 25 years of Year 10 data (nearly 700,000 students), revealing vaping slowed smoking declines: 12.6% ever-smoked in 2023 vs. projected 6.6%, with daily youth vaping surging nine-fold to 10%.
University of Otago research highlights cessation hurdles: interviews with dual-users show nostalgia for cigarettes impedes full switching, sustaining cancer-linked exposure. Their surveys confirm nicotine vaping 2-3x more common than smoking among teens. Massey University tracks trends via NZ Drugs Trends Survey, noting rising nicotine e-liquid use and cessation strategies, informing campus health policies.
Biological Mechanisms: From Aerosol to Tumorigenesis
Vape aerosols deliver nicotine, flavorings (e.g., cinnamaldehyde cytotoxic to oral cells), metals, and carbonyls, absorbed systemically. In lungs and mouth, they induce DNA adducts, mutations (e.g., via nitrosamine ketone), oxidative stress (elevated biomarkers), and chronic inflammation—precursors to adenocarcinoma. Mouse models confirm tumors; human cases link young oral lesions to vaping. Nicotine-free vapes harm via VOCs and flavors, though less severely.
Step-by-step: Inhalation → ultrafine particles penetrate alveoli → chemical reactions generate radicals → epigenetic/epigenomic alterations → proliferative lesions → malignancy. NZ unis' bio-models quantify deposition, aiding risk prediction.
Stakeholder Perspectives: Balancing Harm Reduction and Risks
Cancer Society NZ advocates regulated vaping as smoking cessation aid (less harmful overall) but warns of youth gateway and cancer plausibility.Full report Anti-smoking groups fear backlash pushing smokers back to cigarettes, per RNZ coverage. Experts like Prof Richard Edwards emphasize: non-smokers avoid; smokers switch fully under guidance.
- Health professionals: Monitor biomarkers in high-risk groups.
- Universities: Campus bans, education programs.
- Regulators: Align with Smokefree Aotearoa remnants post-2023 repeal.
Policy Evolution and Smokefree Aotearoa Legacy
NZ's Smokefree 2025 aimed nicotine-free generations but faltered; vaping surged amid lax flavors/access. Post-repeal, pharmacy sales, denicotinisation proposed. New evidence bolsters calls for stringent youth protections, mirroring Australia's moves. Universities advocate evidence-based policy via research influencing Ministry of Health.
Implications for University Students and Campuses
Uni students, peak vaping age, face amplified risks amid stress/peer norms. Campuses report indoor vaping evasion; unis integrate screening in health services. Research positions NZ HE as leaders: Auckland's models forecast student lung function declines; Otago/Massey inform quit programs. Actionable: Peer support, NRT alternatives, awareness via RateMyProfessor-like platforms for health educators.
Future Outlook: Needed Research and Solutions
NZ unis prioritize longitudinal cohorts tracking vapers for cancer incidence, Māori-focused trials, AI-enhanced modeling. Solutions: Flavored bans, nicotine caps, campus clinics. Quitting: Behavioral therapy + NRT outperforms solo vaping per Otago. Outlook: With proactive HE research, NZ can mitigate emerging cancer burden.
For deeper dive, explore the seminal review here and NZ Health Survey data.
